Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

38
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recalibration and Validation of a Risk Scoring Tool to Predict Multidrug-Resistant <i>Pseudomonas aeruginosa</i>.

Open forum infectious diseases·2026
Same author

Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans.

Mutagenesis·2026
Same author

We Cannot Overcome the Mediocrity of Colistin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy.

Pharmacotherapy·2025
Same author

Point-Counterpoint: Cascade reporting-useful tool to support antimicrobial stewardship, or dangerously misleading.

Journal of clinical microbiology·2025
Same author

Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients.

Clinical transplantation·2025

Related Experiment Video

Updated: Sep 9, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.8K

Navigating the Muddled Middle: A Case-Based Exploration of Oral β-Lactams for Systemic Gram-Negative Infections.

Jennifer Shif1, Hawi Tasissa2, Conan MacDougall3

  • 1School of Pharmacy, Temple University, Philadelphia, Pennsylvania, USA.

Open Forum Infectious Diseases
|September 5, 2025
PubMed
Summary

Oral beta-lactams can treat systemic gram-negative infections, challenging their reputation as low-bioavailability drugs. Individual patient factors and risk-benefit analyses guide their appropriate selection.

Keywords:
bacteremiacephalosporingram negativestepdownβ-lactam

More Related Videos

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

10.6K
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.1K

Related Experiment Videos

Last Updated: Sep 9, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.8K
Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

10.6K
Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.1K

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Efficacy

Background:

  • Oral beta-lactams are often perceived as ineffective for systemic gram-negative infections due to low bioavailability.
  • This perception limits their clinical application and exploration for treating such infections.
  • Understanding the nuances of different oral beta-lactam pharmacokinetic/pharmacodynamic (PK/PD) profiles is crucial.

Purpose of the Study:

  • To challenge the notion that oral beta-lactams are universally inferior for systemic gram-negative infections.
  • To present specific clinical scenarios where oral beta-lactams can be effectively utilized.
  • To outline a decision-making framework for selecting or avoiding oral beta-lactams based on risk-benefit assessments.

Main Methods:

  • Review of existing literature on oral beta-lactam PK/PD profiles.
  • Analysis of clinical case studies and treatment guidelines.
  • Development of a risk-benefit analysis model for oral beta-lactam use in specific infection contexts.

Main Results:

  • Demonstrated that PK/PD profiles vary significantly among oral beta-lactam agents.
  • Identified three distinct clinical scenarios where oral beta-lactams show potential utility in treating systemic gram-negative infections.
  • Highlighted that appropriate patient selection and risk assessment are key to successful outcomes.

Conclusions:

  • Oral beta-lactams possess a more nuanced role in treating systemic gram-negative infections than commonly believed.
  • Individualized assessment of PK/PD, patient factors, and risk-benefit analysis is essential for optimizing oral beta-lactam therapy.
  • Further exploration of oral beta-lactams in specific, carefully selected cases is warranted to improve treatment options.